Infirst Healthcare Limited

Peptcell Limited

Tangent Reprofiling Limited

Health Clinics Limited

Biocopea Limited

Infirst Helathcare Limited

Tangent Reprofilling Limited

Gregory Alan Stoloff

Wilson Romero Caparros-Wanderley

Suzanne Jane Dilly

Robin Mark Bannister

John Brew

Olga Pleguezuelos Mateo

Gemma Szucs

Paul Taylor

Wilson Caparros-Wanderely

Olga Pleguezeulos Mateo

Wilson Romero Caparros-Wanderlay

Paul Christopher Taylor

Wilson Caparros Wanderley

Wilson Caparrós-Wanderley

Suzanne Dilly

Wilson Romero CAPARRÓS-Wanderley

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Compositions and methods for treating chronic inflammation and inflammatory diseases

The present specification discloses recombinant nucleic acid constructs encoding an immunogenic multiepitope polypeptide comprising two or more polypeptides, recombinant nucleic acid constructs encoding at least two epitopes from two or more internal proteins of influenza virus, compositions comprising such recombinant nucleic acid constructs and methods of eliciting a T cell immune response against an influenza virus in a vertebrate using such recombinant nucleic acid constructs and compositions.

Influenza peptides and compositions

The present specification discloses pharmaceutical compositions formulated as a suspension for oral administration, the suspension comprising solid particles of a non-steroidal anti-inflammatory drug (NSAID) in an oil carrier comprising one or more free fatty acids, a glycerolipid, and a phospholipid as well as methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Oral suspensions comprising a non-steroidal anti-inflammatory drug (NSAID)

A pharmaceutical composition comprising a cancer therapeutic that is capable of inhibiting and/or reducing the ability of a cancer cell to take up and utilize glucose or other energy source, a lipid or other building block of a cell membrane or organelle, and/or cholesterol. The pharmaceutical composition can comprise one or more cancer therapeutics that can be administered individually or in combination to an individual.

Cancer drug and uses

The present specification disclosesantigens, immunogenic compositions and medicaments comprising suchantigens, methods and uses for suchantigens and immunogenic compositions for treating a-based disease.

Chagas antigens and antibodies and compositions, methods and uses thereof

Peptide sequences and compositions

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.

Compositions and methods for treating cardiovascular diseases

Provided is a polypeptide composition comprising one or more polypeptides, which polypeptides are immunogenic in a vertebrate such that they cause the vertebrate to produce immune system cells capable of recognizing at least one epitope from an arthropod saliva protein fraction, wherein the arthropod saliva protein fraction has a mass of 40 kDA or less, and wherein the polypeptides are selected independently from:

Growing community of inventors

London, United Kingdom

Gregory Alan Stoloff